Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Mar 28, 2017 • 9:00 AM EDT
Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the OmniAb® Technology
Mar 9, 2017 • 8:00 AM EST
Ligand to Participate in Upcoming Investor Conference
Feb 28, 2017 • 4:10 PM EST
Ligand Provides Highlights from Today’s Analyst Day Event
Mar 14, 2017 • 4:30pm EDT
The Ritz-Carlton, Laguna Niguel, Dana Point, CA
See all events
Feb 28, 2017 • 10:00am EDT
New York, NY
Feb 23, 2017 • 4:30pm EDT
Merrimack to present MM-141 and MM-151 data at the 2017 American Association for Cancer Research annual meeting https://t.co/WngoNgJjnb
Melinta and Menarini enter into Commercial/Co-Development Agreement for Delafloxacin (Baxdela) In 68 Countries https://t.co/qN3ZgHtvpz
Biocad receives approval for interferon beta-1a biosimilar in Russia https://t.co/38pQyoIB1m